Shenzhen Kangtai Biological Products Co., Ltd. (SHE:300601)
China · Delayed Price · Currency is CNY 12.58
-0.29 (-2.25%)
Sep 4, 2026, 3:04 PM CST
SHE:300601 Ratios and Metrics
Market cap in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 3, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
| 14,051 | 16,497 | 19,155 | 30,324 | 27,232 | 67,700 | |
Market Cap Growth | -35.45% | -13.88% | -36.83% | 11.35% | -59.77% | -43.30% |
Enterprise Value | 13,292 | 16,717 | 20,961 | 31,692 | 28,013 | 65,942 |
Last Close Price | 12.58 | 14.73 | 16.99 | 26.59 | 30.69 | 59.13 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 3, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
PE Ratio | 158.87 | 234.57 | 94.99 | 35.21 | - | 53.59 |
Forward PE | 71.60 | 70.60 | 20.24 | 22.39 | 22.73 | 50.97 |
PS Ratio | 5.50 | 6.17 | 7.22 | 8.72 | 8.63 | 18.54 |
PB Ratio | 1.45 | 1.71 | 1.98 | 3.18 | 3.03 | 7.39 |
P/TBV Ratio | 1.54 | 1.80 | 2.08 | 3.33 | 3.16 | 7.68 |
P/FCF Ratio | 61.76 | 54.33 | 146.15 | 96.37 | - | - |
P/OCF Ratio | 24.03 | 25.96 | 31.75 | 29.35 | 49.90 | 40.97 |
PEG Ratio | - | 1.56 | 0.52 | 0.99 | 0.99 | 0.96 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 3, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
EV/Sales Ratio | 5.20 | 6.25 | 7.91 | 9.11 | 8.87 | 18.06 |
EV/EBITDA Ratio | 26.94 | 38.42 | 46.87 | 32.35 | 68.98 | 38.68 |
EV/EBIT Ratio | 152.19 | 403.37 | 161.26 | 40.72 | 136.56 | 50.71 |
EV/FCF Ratio | 58.42 | 55.06 | 159.93 | 100.72 | - | - |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 3, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Debt / Equity Ratio | 0.20 | 0.20 | 0.21 | 0.26 | 0.26 | 0.30 |
Debt / EBITDA Ratio | 3.90 | 4.34 | 4.52 | 2.52 | 5.64 | 1.61 |
Debt / FCF Ratio | 8.45 | 6.21 | 15.44 | 7.83 | - | - |
Net Debt / Equity Ratio | -0.08 | -0.08 | -0.06 | 0.07 | 0.03 | -0.17 |
Net Debt / EBITDA Ratio | -1.58 | -1.78 | -1.30 | 0.72 | 0.74 | -0.90 |
Net Debt / FCF Ratio | -3.43 | -2.55 | -4.45 | 2.24 | -0.39 | 1.73 |
Asset Turnover | 0.18 | 0.19 | 0.18 | 0.24 | 0.23 | 0.31 |
Inventory Turnover | 1.14 | 1.10 | 0.90 | 0.87 | 0.87 | 1.54 |
Quick Ratio | 2.68 | 2.37 | 2.04 | 1.66 | 1.84 | 2.35 |
Current Ratio | 3.06 | 2.71 | 2.36 | 1.96 | 2.21 | 2.80 |
Return on Equity (ROE) | 0.83% | 0.73% | 2.10% | 9.30% | -1.46% | 15.19% |
Return on Assets (ROA) | 0.39% | 0.18% | 0.55% | 3.37% | 0.92% | 6.85% |
Return on Invested Capital (ROIC) | 0.87% | 0.46% | 1.34% | 7.30% | 2.43% | 18.79% |
Return on Capital Employed (ROCE) | 0.70% | 0.30% | 1.10% | 6.30% | 1.80% | 11.30% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 3, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Earnings Yield | 0.59% | 0.43% | 1.05% | 2.84% | -0.49% | 1.87% |
FCF Yield | 1.62% | 1.84% | 0.68% | 1.04% | -2.81% | -1.31% |
Dividend Yield | 0.42% | 0.24% | 0.53% | 1.43% | - | 1.22% |
Payout Ratio | 83.21% | 187.05% | 127.26% | 27.54% | - | 17.45% |
Buyback Yield / Dilution | 12.07% | -4.63% | -0.15% | -1.15% | 0.43% | -3.23% |
Total Shareholder Return | 12.49% | -4.39% | 0.38% | 0.28% | 0.43% | -2.02% |